F/M Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

F/M Investments’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-17,599	Closed	-$392K	–	355
2026 Q1	$392K	Sell	17,599 -206,406	-92%	-$4.93M	0.03%	257
2025 Q4	$5.98M	Buy	224,005 +173,423	+343%	+$4.14M	0.23%	106
2025 Q3	$1.08M	Buy	50,582 +2,133	+4%	+$50.4K	0.04%	291
2025 Q2	$1.05M	Sell	48,449 -20,304	-30%	-$377K	0.04%	286
2025 Q1	$1.14M	Buy	68,753 +4,093	+6%	+$74.4K	0.05%	279
2024 Q4	$1.19M	Buy	+64,660	New	+$1.04M	0.04%	275

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

F/M Investments's ACAD Position: Q2 2026 in Review

F/M Investments sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 17,599 shares — an estimated $392K sold.

F/M Investments first reported a position in ACAD in Q4 2024 and held it in 6 quarters. The position peaked at $5.98M in Q4 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

F/M Investments reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
F/M Investments sold 17,599 Acadia Pharmaceuticals shares in Q2 2026, an estimated $392K.
F/M Investments first reported a position in Acadia Pharmaceuticals in Q4 2024 and held it in 6 quarters.
F/M Investments's Acadia Pharmaceuticals position peaked at $5.98M in Q4 2025.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on F/M Investments's 13F filing for Q2 2026, filed 5 Aug 2026.